Ionis Pharmaceuticals (IONS) Getting Somewhat Favorable News Coverage, Analysis Shows
News articles about Ionis Pharmaceuticals (NASDAQ:IONS) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ionis Pharmaceuticals earned a news impact score of 0.17 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.8509640343771 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Why You Should Still Buy Ionis Pharmaceuticals, Inc. (IONS) Stock Today – StockNewsGazette (stocknewsgazette.com)
- Ionis Recommends Shareholders Reject The Below-The-Market Mini-Tender Offer By TRC Capital Corporation – PR Newswire (press release) (prnewswire.com)
- Ionis Pharmaceuticals : Recommends Shareholders Reject the Below the Market Mini Tender Offer by TRC Capital Corporation (4-traders.com)
- Must-Know Developments for Ionis Pharmaceuticals (finance.yahoo.com)
- How Akcea Therapeutics’ Volanesorsen Performed in 2Q17 (finance.yahoo.com)
Several analysts have recently issued reports on the company. Evercore ISI assumed coverage on Ionis Pharmaceuticals in a research note on Wednesday, August 16th. They set an “outperform” rating and a $65.00 price target for the company. Needham & Company LLC reiterated a “buy” rating and set a $64.00 price target on shares of Ionis Pharmaceuticals in a research note on Wednesday, July 26th. Cowen and Company reiterated a “market perform” rating on shares of Ionis Pharmaceuticals in a research note on Monday, May 22nd. Stifel Nicolaus upped their price target on Ionis Pharmaceuticals from $42.00 to $50.00 and gave the stock a “hold” rating in a research note on Wednesday, August 9th. Finally, Jefferies Group LLC reiterated an “underperform” rating and set a $18.00 price target (up previously from $17.00) on shares of Ionis Pharmaceuticals in a research note on Thursday, August 10th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and seven have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $48.91.
Ionis Pharmaceuticals (NASDAQ IONS) opened at 47.99 on Monday. Ionis Pharmaceuticals has a 12-month low of $24.58 and a 12-month high of $60.01. The firm has a 50-day moving average price of $50.97 and a 200 day moving average price of $47.20. The firm has a market cap of $5.97 billion, a PE ratio of 230.72 and a beta of 3.14.
Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.09) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by $0.03. The business had revenue of $104.15 million during the quarter, compared to the consensus estimate of $93.29 million. Ionis Pharmaceuticals had a return on equity of 15.52% and a net margin of 5.25%. The firm’s quarterly revenue was up 170.7% on a year-over-year basis. During the same period last year, the business posted ($0.47) earnings per share. Equities research analysts forecast that Ionis Pharmaceuticals will post ($0.20) EPS for the current year.
In related news, SVP C Frank Bennett sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $59.29, for a total value of $592,900.00. Following the completion of the transaction, the senior vice president now directly owns 25,041 shares of the company’s stock, valued at approximately $1,484,680.89. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Ionis Pharmaceuticals Inc acquired 3,125,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 19th. The stock was acquired at an average cost of $8.00 per share, with a total value of $25,000,000.00. Following the completion of the acquisition, the insider now owns 28,884,540 shares in the company, valued at approximately $231,076,320. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 54,379 shares of company stock valued at $2,946,052. 1.86% of the stock is owned by insiders.
WARNING: “Ionis Pharmaceuticals (IONS) Getting Somewhat Favorable News Coverage, Analysis Shows” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://theolympiareport.com/2017/08/28/ionis-pharmaceuticals-ions-getting-somewhat-favorable-news-coverage-analysis-shows.html.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.